Search

Your search keyword '"Bengel FM"' showing total 403 results
Start Over Author "Bengel FM"
403 results on '"Bengel FM"'

19. Impaired myocardial blood flow and coronary flow reserve of the anatomical right systemic ventricle in patients with congenitally corrected transposition of the great arteries

Author

Hauser, M, Bengel, FM, Hager, A, Kuehn, A, Nekolla, SG, Kaemmerer, H, Schwaiger, M, and Hess, J

Subjects
Congenital heart disease -- Evaluation -- Methods -- Usage, Transposition of great arteries -- Evaluation -- Methods -- Usage, PET imaging -- Methods -- Usage, Blood flow -- Evaluation -- Usage -- Methods, Statistics -- Methods -- Usage, Health
Abstract

Objectives: To investigate myocardial blood flow of the morphological right systemic ventricle in unoperated patients with congenitally corrected transposition of the great arteries (CCTGA) by positron emission tomography (PET). Design: [...]

Published
2003

27. Die Wertigkeit der PET-CT in der Ausbreitungsdiagnostik maligner Kopf-Hals-Tumoren

Author

Thielker, J, Durisin, M, Bengel, FM, Derlin, T, Lenarz, T, and Helmstädter, V

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Wertigkeit der PET-CT zur Diagnostik cervikaler Lymphknotenmetastasen im Rahmen einer Ausbreitungsdiagnostik bei malignen Kopf-Hals-Tumoren sowie im Rahmen posttherapeutischer Verlaufskontrollen wird rege diskutiert. Einige Studien schreiben der PET-CT eine Sensitivität von bis [zum vollständigen Text gelangen Sie über die oben angegebene URL], 88. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie

Published
2017
Full Text
View/download PDF

28. Anatomic versus Physiologic Assessment of Coronary Artery Disease: Role of CFR, FFR, and PET Imaging in Revascularization Decision-Making

Author

Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, CAMICI , PAOLO, Cerqueira MD, Chow BJW, Di Cali MF, Dorbala S, Gewirtz H, Gropler RJ, Kaufmann PA, Knaapen P, Knuuti J, Merhige ME, Rentrop KP, Ruddy TD, Schelbert HR, Shindler TH, Schwaiger M., Gould, Kl, Johnson, Np, Bateman, Tm, Beanlands, R, Bengel, Fm, Bober, R, Camici, Paolo, Cerqueira, Md, Chow, Bjw, Di Cali, Mf, Dorbala, S, Gewirtz, H, Gropler, Rj, Kaufmann, Pa, Knaapen, P, Knuuti, J, Merhige, Me, Rentrop, Kp, Ruddy, Td, Schelbert, Hr, Shindler, Th, and Schwaiger, M.

Published
2013

29. Rb-82 PET myocardial perfusion imaging is superior to Tc-99m-labelled agent SPECT in patients with known or suspected coronary artery disease

Author

Flotats, A, Bravo, PE, Fukushima, K, Chaudhry, MA, Merrill, J, and Bengel, FM

Subjects
Positron emission tomography, Attenuation correction, Myocardial perfusion imaging, Single photon emission computed tomography, Coronary artery disease
Abstract

We compared the quality, interpretive confidence and interreader agreement between SPECT and PET myocardial perfusion imaging (MPI) in the same group of patients. The study group comprised 27 patients (age 55 +/- 8.5 years, 12 men) with known or suspected coronary artery disease (CAD) who had undergone gated rest/stress MPI with Tc-99m-labelled agent SPECT (with and without attenuation correction, AC), and subsequent clinical confirmation with Rb-82 PET. Three experienced readers blinded to the clinical information interpreted all MPI studies. Interreader agreement was significantly superior for PET studies than for SPECT studies. Following consensus interpretation, the quality of 22 % of the non-AC SPECT studies, 33 % of the AC SPECT studies and 63 % of the PET studies was assessed as excellent or good (p = 0.016). Interpretations were definitely normal or abnormal in 7 % of non-AC SPECT studies, 30 % of AC SPECT studies and 85 % of PET studies (p = 0.046). In 13 patients who had received either invasive coronary angiography or CT angiography with no significant CAD, the true-positive rate for significant CAD was higher for PET, and the true-negative rate was equal for PET and AC SPECT, and lower for non-AC SPECT. Rb-82 PET MPI, used as a confirmatory test after SPECT, offers improved image quality, interpretive confidence and interreader agreement.

Published
2012

30. Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)-C-11-CGP12388

Author

Momose, M, Reder, S, Raffel, DM, Watzlowik, P, Wester, HJ, Nguyen, N, Elsinga, PH, Bengel, FM, Remien, J, Schwaiger, M, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
MYOCARDIAL-ISCHEMIA, DOWN-REGULATION, ADRENERGIC-RECEPTOR, Langendorff, IN-VITRO, DILATED CARDIOMYOPATHY, ADRENOCEPTOR DENSITY, CGP-12177, CGP12388%22">(S)-CGP12388, beta-adrenoreceptor density, PET, POSITRON-EMISSION-TOMOGRAPHY, C-11-CGP12388, isolated rat heart
Abstract

(S)-C-11-CGP12388 (C-11-CGP12388) was recently developed as an in vivo PET tracer for the evaluation of cardiac beta-adrenergic receptors. The purpose of this study was to evaluate the myocardial kinetics of C-11-CGP12388 using the perfused rat heart model. Methods: Normal rat hearts were cannulated for retrograde perfusion according to the Langendorff method. Studies were performed using constant coronary flow rates of 12 mL/min (high flow: n = 6) and 6 mL/min (low flow: n = 6). beta-Adrenergic-blocking studies were also done using propranolol (blocking: n = 6). Two bolus injections of C-11-CGP12388 were administered at a 25-min interval, and time-activity curves were measured using bismuth germanate detectors. The beta-adrenergic receptor density (B-max) and total distribution volume (DVtot) were estimated using compartmental modeling. After the experiment, B-max in vitro was measured for all hearts using H-3-CGP12177, and the values were compared with the B-max estimated in isolated hearts. Results: DVtot was significantly lower in the blocking group than in the high-flow group (P

Published
2004

32. Peptidrezeptor-Radionuklid-Therapie bei Neuroendokrinen Tumoren in Deutschland: Erste Ergebnisse eines multizentrischen Krebsregisters

Author

Hörsch, D, primary, Ezziddin, S, additional, Haug, A, additional, Gratz, KF, additional, Dunkelmann, S, additional, Krause, BJ, additional, Schümichen, C, additional, Bengel, FM, additional, Knapp, WH, additional, Bartenstein, P, additional, Biersack, HJ, additional, Plöckinger, U, additional, and Baum, RP, additional

Published
2012
Full Text
View/download PDF

35. Effects of nateglinide on myocardial microvascular reactivity in type 2 diabetes mellitus -- a randomized study using positron emission tomography.

Author

Bengel FM, Abletshauser C, Neverve J, Schnell O, Nekolla SG, Standl E, and Schwaiger M

Abstract

AIMS: To evaluate effects of the oral antidiabetic insulinotropic agent nateglinide on myocardial blood flow (MBF) and microvascular reactivity in Type 2 diabetic patients. METHODS: Forty-seven Type 2 diabetic patients were randomly assigned 2 : 1 to nateglinide 120 mg (t.i.d., n = 33) or placebo (n = 14). At baseline and after 16 weeks of treatment, MBF was quantified using positron emission tomography with N-13 ammonia at rest, during endothelial-dependent stimulation by cold pressor test and during adenosine-mediated vasodilation. Additional blood samples were taken to assess glycaemic control and lipid profile. RESULTS: MBF at rest and during adenosine did not change during the study. The percentage of flow increase from rest during cold pressor test did not improve significantly in the nateglinide group vs. placebo (from 26.1 +/- 37.2% to 29.1 +/- 27.8% between week 0 to week 16 for nateglinide vs. 14.9 +/- 37.1% to 18.1 +/- 28.4% for placebo; P = 0.07 for nateglinide when adjusted for higher baseline values). Nateglinide decreased HbA1c by 0.4% (from 7.6 +/- 0.9% to 7.2 +/- 1.3%) compared to an increase of 0.5% in the placebo group (from 7.9 +/- 0.8% to 8.4 +/- 1.7%; P = 0.02 for nateglinide). No differences between the two groups were observed in insulin levels and lipid status. CONCLUSIONS: Nateglinide neither improved, nor impaired myocardial blood flow in Type 2 diabetic patients. Potential effects on endothelial-dependent myocardial blood flow remain to be investigated further. Positron emission tomography is a sensitive approach to assess the effects of therapeutic agents on myocardial blood flow in patients with diabetes. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results